Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSI 136 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Subject on active drug |
| 2 | PLACEBO_COMPARATOR | Subject on placebo |
| GSI 136 | EXPERIMENTAL | - |
| placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GSI-136 | DRUG | - |
| Placebo | OTHER | - |
| GSI 136 | DRUG | - |
\<Inclusion: 1. Men or women of nonchildbearing potential (WONCBP) aged 18 to 50 years or greater than 65 years, inclusive, at screening. WONCBP may be included if they are either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for greater than 1 year (with follicle-stimulat...
Top 20 of 24 competitors
GSI 136 is an investigational small molecule being developed by Pfizer for Alzheimer Disease. It is currently in Phase 1 clinical development, meaning it is still being tested in early-stage trials and is not yet approved for use.
GSI 136 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting Phase 1 clinical trials to evaluate the safety and tolerability of the drug in healthy volunteers.
GSI 136 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy volunteers, with a total enrollment of 152 participants. The drug is investigational and has not been approved by regulatory authorities.
GSI 136 has been studied in two completed Phase 1 trials: NCT00718731, which enrolled 80 healthy young and elderly subjects in the United States, and NCT00719394, which enrolled 72 healthy young and elderly Japanese males in Japan. Both trials were randomized, double-blind, and placebo-controlled.
Yes, GSI 136 and GSI-136 refer to the same investigational drug. The clinical trial NCT00718731 uses the name GSI-136, while NCT00719394 uses GSI 136. Both trials are Phase 1 studies sponsored by Pfizer in healthy volunteers.